¹³¹I therapy for elevated thyroglobulin levels

Assuming that the fractional uptake is the same, both after the administration of a diagnostic and a therapeutic activity, ¹³¹I uptake too low to be detected with 2-5 mCi may become detectable after the administration of 100 mCi. This should be performed routinely in patients with thyroglobulin levels above approximately 5 ng/mL during L-Thyroxine (LT₄) treatment or 10 ng/mL off LT₄ treatment for three main reasons: 1) in 80% of these patients, a post-therapy ¹³¹I total body scan showed loci of uptake in the neck or at distant sites, whereas in the other patients, metastases emerged clinically some years later; 2) ¹³¹I is not the only treatment modality, and, for instance, lymph node metastases may warrant further surgery; and 3) from a dosimetric point of view, the relevant parameter is the concentration of ¹³¹I, i.e., the ratio between the uptake and the mass of functioning tissue: a low uptake in a small metastasis may result in a higher ¹³¹I concentration than a higher uptake in a much larger metastasis.